AAV9-Synapsin-Caveolin-1 (Eikonoklastes)

N/A

Report date: 2024/02/05 13:26:18

Base Information

Drug NameAAV9-Synapsin-Caveolin-1 (Eikonoklastes)
Drug Alias NameAAV9-SynCav1 (Eikonoklastes)SYNCAV1SynCav1ET-101 (Eikonoklastes)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionCaveolin-1 gene transference
TargetsCaveolin-1
Therapy Area/IndicationsAmyotrophic Lateral SclerosisAlzheimer DiseaseBrain Injuries, Traumatic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEikonoklastes Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEikonoklastes Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisAlzheimer DiseaseBrain Injuries, Traumatic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A